Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
Steven Grinspoon(Massachusetts General Hospital), Pamela S. Douglas(Duke University), Heather J. Ribaudo(Cancer Research And Biostatistics), Carl J. Fichtenbaum(Cancer Research And Biostatistics), Edgar T. Overton(University of Alabama at Birmingham), Craig A. Sponseller, Udo Hoffmann(Duke Medical Center), Katharine Cooper‐Arnold(National Institutes of Health), Michael T. Lu(Cancer Research And Biostatistics), Patrice Desvigne‐Nickens(National Heart Lung and Blood Institute), Karin L. Klingman(National Institutes of Health), Carlos Malvestutto(The Ohio State University Wexner Medical Center), Judith S. Currier(University of California, Los Angeles), Kathleen V. Fitch(Harvard University), Judith A. Aberg(Icahn School of Medicine at Mount Sinai), Beverly Alston‐Smith(Cancer Research And Biostatistics), Myron A. Waclawiw(National Institutes of Health), Markella V. Zanni(Harvard University)
Cited by 153
Related Papers
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
|New England Journal of Medicine|2010|7.2k
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary
|Circulation|2012|2.4k
Two-Year Outcomes after Transcatheter or Surgical Aortic-Valve Replacement
|New England Journal of Medicine|2012|2.3k